PATH and its partners are in the early stages of developing microarray patches (MAPs) containing cabotegravir for HIV pre-exposure prophylaxis (PrEP), as well as a MAP containing cabotegravir and a contraceptive—a multipurpose protection technology (MPT).
Corporate author(s): PATH
Publication date: February 2018
509 KB PDF
Hard copies are available.
Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.
Related regions: Global
- About PATH's work > Advancing technologies
- Emerging and epidemic diseases > HIV and AIDS
- Health technologies > Miscellaneous
- Reproductive health > Sexually transmitted infections
For more information…
Contact: PATH Publications
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA